體外診斷 (IVD) 趨勢與市場趨勢 (2025)

In Vitro Diagnostic (IVD) Trends and Market Update, 2025

出版日期: 2025年12月02日 | 出版商:

Kalorama Information | 英文 98 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

Kalorama Information 發布的 "體外診斷 (IVD) 趨勢與市場趨勢 (2025)" 報告深入分析了在全球經濟不確定性背景下不斷發展的 IVD 市場。該報告每年發布兩次（4 月和 12 月），緊接著 Kalorama 的旗艦研究報告 "全球體外診斷 (IVD) 市場，第 18 版" 之後，既是獨立的資訊來源，也是診斷產業決策者的策略補充。

在技術創新和不斷增長的醫療需求的推動下，2025 年 IVD 市場將繼續保持成長勢頭。下一代定序 (NGS)、微流控技術和精準醫療的創新正在變革診斷方式，使癌症和遺傳疾病等複雜疾病的檢測能夠實現高度精確、靈敏和個人化。伴隨診斷和多重檢測的普及凸顯了以患者為中心的醫療模式和對疾病更深入理解的趨勢。

吸引業界關注的關鍵成長領域包括即時檢測、癌症診斷、伴隨診斷技術、免疫化學和質譜分析。核酸檢測、基因檢測和HPV分子診斷預計將大幅成長，並將塑造體外診斷的未來。

本報告提供以下方面的實用見解：

市場推動因素與關鍵產業趨勢
新產品開發引領創新
競爭格局與主要參與者策略
新興機會與高成長領域

基於專家分析和最新數據，Kalorama為企業高管、行業領導者和投資者提供工具，幫助他們應對監管挑戰、利用技術進步並在充滿活力的體外診斷領域中識別盈利機會。

Kalorama Information's In Vitro Diagnostic (IVD) Trends and Market Update, 2025 delivers critical insights into the evolving IVD market amid global economic uncertainties. Published twice annually-in April and in December following the release of Kalorama's flagship study, The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition-this report serves as both a standalone resource and a strategic companion for decision-makers in the diagnostics industry.

The 2025 IVD market continues its growth trajectory, fueled by technological breakthroughs and rising healthcare demands. Innovations in next-generation sequencing (NGS), microfluidics, and precision medicine are transforming diagnostics, enabling highly accurate, sensitive, and personalized testing for complex conditions such as cancer and genetic disorders. The surge in companion diagnostics and multiplex testing underscores a shift toward patient-centric care and deeper disease insights.

Key growth segments attracting industry attention include Point-of-Care testing, cancer diagnostics, companion diagnostics technologies, immunochemistry, and mass spectrometry. Nucleic acid assays, gene testing, and HPV molecular diagnostics are poised for significant expansion, shaping the future of IVD.

This report provides actionable intelligence on:

Market drivers and major industry trends
New product developments shaping innovation
Competitive landscape and key player strategies
Emerging opportunities and high-growth segments

With expert analysis and up-to-date data, Kalorama equips executives, industry leaders, and investors with the tools to navigate regulatory challenges, capitalize on technological advancements, and identify profitable opportunities in the dynamic IVD sector.

Chapter 1: Worldwide IVD Market - December 2025 Update

About Kalorama Information
IVD Market Demand and Growth
- Figure 1-1: Q1-Q3 IVD Segment Performance Commentary, 2025 [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology (Molecular), Point-of-Care (POC)]
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2025 ($ million) [Blood Bank Molecular - NAT Screens; Blood Grouping/Typing; Circulating Tumor Cells; Clinical Chemistry; Coagulation (PT/INR); Coagulation, Molecular; D-dimer; Diabetes HbA1c, lab; Drugs of Abuse; Hematology - Core Lab; Histology/Cytology; HPV, Molecular; Immuno - Blood Bank Screening; Immuno-Infectious Disease; Immunoassays - Non-isotopic; Mass Spectrometry; Microbiology (ID/AST); Microbiology (Molecular); Microbiology - Mass Spectrometry; NAAT - Oncology; Nucleic Acid Assays - Genetic/Inherited; Other Immunos; POC, OTC Diabetes; POC, OTC Other; POC, Professional/Hospital]
- Figure 1-2: IVD Segment Performance, Q1 2025-Q4 2025 estimated ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, Point-of-Care (POC), Other]
- Figure 1-3: IVD Segment Performance, Total Market Value, 2025 estimated ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, Point-of-Care (POC), Other]
- COVID-19 Diagnostic Markets
  - Table 1-2: COVID-19 Product Sales, 2025 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and including COVID-19, 2025 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2025 (%) [COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments]
- Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2025 estimated ($ million)
- Table 1-4: Global In Vitro Diagnostic Market - YoY Growth, 2024-2025 (%) [Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Circulating Tumor Cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, Molecular, D-dimer, Diabetes HbA1c, Lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, HPV, Molecular, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Immunoassays- non-isotopic, Microbiology (ID/AST), Microbiology (Molecular), Microbiology - Mass Spectrometry, NAAT - Oncology, Nucleic Acid Assays - Genetic/Inherited, Other Immunos, POC, OTC Diabetes, POC, OTC Other, POC, Professional/Hospital]
- Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2024-2025 (%) [Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Circulating Tumor Cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, Molecular, D-dimer, Diabetes HbA1c, Lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, HPV, Molecular, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Immunoassays- non-isotopic, Microbiology (ID/AST), Microbiology (Molecular), Microbiology - Mass Spectrometry, NAAT - Oncology, Nucleic Acid Assays - Genetic/Inherited, Other Immunos, POC, OTC Diabetes, POC, OTC Other, POC, Professional/Hospital

Chapter 2: Product Trends and New Developments

Selected New - Q3 2025 - Core IVD Product Launches, Developments and Trends
- Immunoassay
- Mass Spectrometry
- Molecular
- Personalized Medicine
- POC
- Coagulation
- Flow Cytometry
- Sequencing
Selected COVID-19 Developments - Q3 2025
- Antigen/Antibody
- Molecular

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2024-2025 (%)
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2022-2025 estimated (%)
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2023-2025 estimated ($ million)
Q3 2025 M&A Activity
- Table 3-1: Q3 2025 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
Roche Diagnostic
- Table 3-8: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-9: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-10: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-11: Thermo Fisher Scientific Corporate Summary